Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
T421616-1ml
|
1ml |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$241.90
|
|
BTK Inhibitors
| Synonyms | 1439901-97-9 | Tirabrutinib hydrochloride | ONO-4059 Hydrochloride | Tirabrutinib HCl | Tirabrutinib (hydrochloride) | ONO-4059 (hydrochloride) | ONO4059 hydrochloride | GS-4059 hydrochloride | Ono-4059(HCl salt) | U374135N48 | 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7 |
|---|---|
| Specifications & Purity | 10mM in DMSO |
| Biochemical and Physiological Mechanisms | Tirabrutinib Hydrochloride (ONO-4059, GS-4059) is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM. |
| Storage Temp | Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Information tirabrutinib(ONO-4059) hydrochloride Tirabrutinib Hydrochloride (ONO-4059, GS-4059) is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM. Targets BTK 2.2 nM In vitro ONO-4059 covalently binds to BTK, and reversibly blocks BCR signaling and B-cell proliferation and activation. It has greater selectivity for BTK than Lck, Fyn, LynA and ONO/GS-4059 only inhibits anti-IgM-induced B-cell activation in a concentration-dependent manner but not inhibit anti-CD3/CD28-induced activation of T-lymphocytes from human PBMCs. ONO/GS-4059 inhibits cell proliferation in some malignant B-cell lines but also induces classical apoptosis at nanomolar concentration in the activated-B cell (ABC) DLBCL cell line, TMD8. In vivo ONO-4059 demonstrates therapeutic efficacy in a mouse CIA model by suppressing generation of inflammatory chemokines and cytokines including IL-6, IL-8, and TNFα by monocytes, and accompanied by regression of cartilage erosion, bone damage, and pannus formation. In pre-clinical models, and in the clinic in both CLL and NHL patients, It exerts its anti-tumour activity, with a favourable safety profile along with promising efficacy over a long duration. Cell Research(from reference) Cell lines:DLBCL cell lines TMD8 cells Concentrations:320 nM Incubation Time:48 h |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Benzene and substituted derivatives |
| Subclass | Diphenylethers |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Diphenylethers |
| Alternative Parents | Diarylethers Phenylimidazoles Purinones 6-aminopurines Phenoxy compounds Phenol ethers N-acylpyrrolidines Aminopyrimidines and derivatives Imidolactams N-substituted imidazoles Heteroaromatic compounds Tertiary carboxylic acid amides Ureas Amino acids and derivatives Azacyclic compounds Hydrochlorides Hydrocarbon derivatives Carbonyl compounds Primary amines Organic oxides |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Diphenylether - Diaryl ether - 1-phenylimidazole - 6-aminopurine - Purinone - Imidazopyrimidine - Purine - Phenoxy compound - N-acylpyrrolidine - Phenol ether - Aminopyrimidine - Imidolactam - Pyrimidine - N-substituted imidazole - Azole - Heteroaromatic compound - Imidazole - Tertiary carboxylic acid amide - Pyrrolidine - Amino acid or derivatives - Carboxamide group - Urea - Organoheterocyclic compound - Ether - Azacycle - Carboxylic acid derivative - Primary amine - Organic oxide - Hydrochloride - Organic oxygen compound - Carbonyl group - Hydrocarbon derivative - Organic nitrogen compound - Organonitrogen compound - Organooxygen compound - Amine - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group. |
| External Descriptors | Not available |
|
|
|
| ALogP | 3.706 |
|---|---|
| HBD Count | 1 |
| Rotatable Bond | 5 |
| IUPAC Name | 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one;hydrochloride |
|---|---|
| INCHI | InChI=1S/C25H22N6O3.ClH/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19;/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28);1H/t18-;/m1./s1 |
| InChIKey | UQYDCIJFACDXSG-GMUIIQOCSA-N |
| Smiles | CC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N.Cl |
| Isomeric SMILES | CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N.Cl |
| PubChem CID | 71571562 |
| Molecular Weight | 490.94 |
| Sensitivity | Moisture sensitive |
|---|---|
| DMSO(mg / mL) Max Solubility | 98 |
| DMSO(mM) Max Solubility | 199.6170611 |
| Water(mg / mL) Max Solubility | <1 |
| Molecular Weight | 490.900 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 490.152 Da |
| Monoisotopic Mass | 490.152 Da |
| Topological Polar Surface Area | 105.000 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 825.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 2 |